EMA’s clearance of AZ vaccine in all adults leaves countries option to restrict among older adults

EMA’s conditional authorization of AstraZeneca’s COVID-19 vaccine for all adults leaves open the possibility that member states could still recommend against its use in older populations where efficacy has not been fully established.

The decision quickly followed a recommendation from EMA’s CHMP on Friday that COVID-19 Vaccine AstraZeneca (AZN1222) gain the conditional authorization in people aged 18 and older. AstraZeneca plc (LSE:AZN; NYSE:AZN) is developing the adenovirus-based vaccine in partnership with the University of Oxford...